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Abstract. M icrobia l seconda r y met abol ites have
emerged as alternative novel drugs for the treatment of
human cancers. Violacein, a purple pigment produced
by Chromobacterium violaceum, was investigated in the
present study for its anti‑tumor properties in tumor cell
lines. Clinically applicable concentrations of violacein were
demonstrated to inhibit the proliferative capacity of tumor
cell lines according to a crystal violet proliferation assay. The
underlying mechanism was the promotion of apoptotic cell
death, as indicated by poly(ADP ribose) polymerase cleavage
and p44/42 mitogen‑activated protein kinase signaling determined by western blot analysis. Collectively, this provided
mechanistic evidence that violacein elicits extracellular-signal
regulated kinase‑induced apoptosis via the intrinsic pathway.
The anti‑malignant properties of violacein in the present study
were further demonstrated by its inhibitory effects on brain
tumor cell migration, specifically glioblastomas, one of the
most invasive and therapeutically resistant neoplasms in the
clinic. Additionally, solid tumors examined in the present
study displayed differential cellular responses and sensitivities
to violacein as observed by morphologically induced cellular
changes that contributed to its anti‑migratory properties. In
conclusion, violacein is a novel natural product with the potential to kill several types of human tumor cell lines, as well as
prevent disease recurrence by antagonizing cellular processes
that contribute to metastatic invasion.
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Introduction
The utility of bacteria as agents for the treatment of cancer was
described over a century ago and continues to be investigated
for their therapeutic value as delivery agents for anti‑cancer
drugs and vectors for gene therapy (1-3). Additionally,
contemporary strategies have also studied the use of bacterial
products, including proteins, enzymes, immunotoxins and
secondary metabolites for their anti‑tumor properties (1-3). An
advantage of these alternatives is the lack of systemic infection associated with the use of live, attenuated and engineered
bacterial strains for cancer therapy (1-3).
In the present study, the secondary metabolite violacein, a
pigment produced by the bacteria Chromobacterium violaceum, was investigated as an anti‑tumor agent, which has been
shown to have medicinal applications as an antibiotic and
anti-trypanosoma agent (4,5). The use of bacterial metabolites such as violacein as anti‑cancer agents is supported by
pre‑clinical studies with other microbial products, including
farnesyltransferase inhibitors (6-14), prodigines (15-17) and
epothilones (18-22), which have displayed positive therapeutic
efficacy in several types of cancer and were subsequently
examined in phase I and II clinical trials. More specifically,
violacein has been shown to have anti‑cancer properties in
leukemia (23,24) and colon cancer cells (25-27), as well as in
Ehrlich ascites tumors by Bromberg et al (28) using an in vivo
mouse model. In contrast to these studies, the present study
used violacein extracted from a Chromobacterium violaceum
strain native to a copper basin in Tennessee, which was demonstrated here to have anti‑proliferative effects on cell lines
derived from solid tumors, as well as displayed an inhibitory
effect on cancer cell migration, extending the anti‑tumorigenic
properties of this bacterial‑produced metabolite.
Materials and methods
Cell conditions and reagents. U87 (glioblastoma), A549
(lung) and MCF7 (breast) cancer cells were purchased from
the American Type Culture Collection (Manassas, VA, USA).
All cell lines were maintained in Dulbecco's Modified Eagle's
Medium (DMEM; Invitrogen Life Technologies, Carlsbad,
CA, USA) containing 10% fetal bovine serum (Invitrogen
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Life Technologies), 2 mM L-glutamine (Invitrogen Life
Technologies), 100 nM MEM non-essential amino acids
(Invitrogen Life Technologies) and penicillin-streptomycin
(Invitrogen Life Technologies) at 37˚C and 5% CO2.
Isolation and characterization of violacein. Chromobacterium
violaceum was collected from environmental soil and
water samples at the Tennessee Copper Mining Company
site (Ducktown, TN, USA), also termed the Copper Basin.
Chromobacterium violaceum were inoculated in LuriaBertani broth (LB) media, streaked and grown on agar plates
for 48 h at 30˚C, until colonies formed. The colonies were
subsequently selected and grown as cultures in LB broth
media for 24-48 h at 30˚C. The cultures were used to extract
and purify violacein, as described previously (29). Cultures
were centrifuged at 14,629 x g in 100% ethanol for 15 min
at 4˚C and the supernatant was collected, and violacein was
separated and extracted using chloroform. The violacein was
allowed to dry for 24 h and dissolved in 50% ethanol (Fisher
Scientific, Fair Lawn, NJ, USA). Violacein was subsequently
purified with reverse phase column chromatography and characterized by liquid chromatography-mass spectrometry and
ultraviolet-visible spectroscopy.
Crystal violet cell proliferation assay. Cells were plated in
24‑well plates, treated with 250 nM, 500 nM and 1 µM violacein
and allowed to incubate for 48 h ([vehicle controls were treated
with dimethyl sulfoxide (DMSO; Amresco, LLC, Solon, OH,
USA)] for dose-response experiments. For time-course experiments, cells were treated with 1 µM violacein and allowed
to incubate for 1, 3 and 5 days. Subsequently, tissue culture
medium was removed, the cell monolayer was fixed with
100% methanol for 5 min and stained with 0.5% crystal violet
in 25% methanol for 10 min. Cells were then washed three
times for 5 min each with distilled water to remove excess
dye and allowed to dry overnight at room temperature. The
incorporated dye was then solubilized in 0.1 M sodium citrate
(Sigma-Aldrich; St. Louis, MO, USA) in 50% ethanol. Next,
100 µl treated and control samples were transferred to 96‑well
plates and optical densities read at 540 nm using an X-mark
microplate absorbance spectrophotometer (Bio-Rad, Hercules,
CA, USA).
Cell motility. Motility assays were conducted according to
the manufacturer's instructions (Cell Biolabs Inc., San Diego,
CA, USA). A cell suspension containing 0.5-1.0x106 cells/ml
was prepared in serum‑free media with vehicle (DMSO) or
1 µM violacein, while 500 µl of media containing 10% fetal
bovine serum was added to the lower chamber of the migration plate. 300 µl of the cell suspension containing vehicle or
1 µM violacein was then added to the inside of each insert
and allowed to incubate for 24 hours at 37˚C and 5% CO2.
Subsequently, non-migratory cells were removed from the
plate inserts (per manufacturer's instructions), migratory cells
were counterstained, solubilized, and optical density densities
read at 595 nm using a X-mark microplate absorbance spectrophotometer (Bio-Rad Laboratories).
Western blot analysis. Cells were plated and treated with
1 µM violacein for 24 h or vehicle (DMSO), rinsed with

Figure 1. Dose response and sensitivity of solid tumor cell lines to violacein.
Violacein caused a significant decrease in cell viability of U87 brain tumor
cells and A549 lung cancer cells in contrast to MCF7 breast cancer cells.
Shown is a dose-response experiment performed in duplicate representative
of three independent experiments that showed similar results. White bars,
vehicle dimethyl sulfoxide; black bars, 1 µM violacein; dark grey bars,
500 nM violacein; light grey bars, 250 nM violacein. Error bars represent the
standard error. *P<0.05 compared to vehicle‑treated control cells.

phosphate-buffered saline (Bio‑Rad Laboratories, Hercules,
CA, USA), and lysed with CelLytic M Cell lysis reagent
(Sigma-Aldrich, St Louis, MO, USA). Protein concentrations
were subsequently determined using the Bradford reagent
(cat. no. B6916; Sigma‑Aldrich). Proteins were separated by
8% SDS-PAGE (Bio‑Rad Laboratories) and then transferred
to nitrocellulose membranes. For immunoblotting, nitrocellulose membranes were incubated with phosphorylated (p)
Akt (rabbit monoclonal; cat. no. 4606), cleaved poly(ADP
ribose) polymerase (PARP; rabbit polyclonal; cat. no. 9544),
p44/42 (rabbit monoclonal; cat. no. 4370), and pS6-ribosomal
protein (rabbit monoclonal; cat. no. 4858) and β‑actin (rabbit
polyclonal; cat. no. 4967), purchased from Cell Signaling
Technology (Danvers, MA, USA) and all diluted 1:25, recognizing target proteins overnight at 4˚C. The membranes were
then incubated with a horseradish peroxidase-conjugated
goat anti‑rabbit secondary antibody (1:100; cat. no. 7074; Cell
Signaling Technology) for 3 h at room temperature, analyzed
using an enhanced chemiluminescence detection system
with SuperSignal West Pico Chemilluminescent Substrate
(cat. no. 34080; Thermo Fisher Scientific, Waltham, MA, USA)
and visualized by autoradiography using a BioSpectrum UVP
Imaging System (BioSpectrum, Upland, CA, USA). Actin was
used as loading control.
Statistical analysis. Values are expressed as the mean ± standard error. Significance was determined using Student's t-test.
P<0.05 was considered to indicate a statistically significant
difference between values.
Results
Violacein antagonizes brain, lung and breast cancer cell
proliferation. Lung and breast cancer are two of the most
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Figure 2. Anti-proliferative effects of violacein on cancer cells. The mitotic
capacity of U87 brain tumor and A549 lung cancer cells was inhibited in
response to treatment with 1 µM violacein, while violacein decreased the
proliferative rate of MCF7 breast cancer cells. Values are representative of
three independent experiments performed in duplicate that showed similar
results. Diamonds, vehicle dimethyl sulfoxide; squares, 1 µM violacein. Error
bars represent the mean±standard error. *P<0.05 compared to vehicle‑treated
control cells at the corresponding time‑point. OD, optical density.

common types of cancer found in men and women, and have
high incidence of metastasis to the brain (30). The present
study therefore evaluated the effects of violacein on three
solid tumor cell lines, U87 (brain), A549 (lung) and MCF7
(breast). Dose-response experiments were performed at the
outset to assess the effects of several violacein concentrations
(250 nM, 500 nM and 1 µM) on cell viability. Cell viability
dose‑response assays revealed a 56-, 34- and 12%-decrease
in U87 cells treated with 1 µM, 500 nM and 250 nM violacein as compared to the viability of vehicle treated control
cells, respectively, while A549 cells displayed a 54, 11 and
8%-decrease in viability when treated with identical concentrations compared to that of vehicle-treated control cells
(Fig. 1). By contrast, MCF7 cell viability did not decrease in
response to violacein exposure using this assay.
The anti‑proliferative effects of violacein have been
attributed to its ability to elicit a cytotoxic response in
several human cancers (23,27,31-33), as well as induce
differentiation, a cytostatic response observed in leukemia
cells by Melo et al (26). To gain better insight into the effect
of violacein on cell proliferation in brain, lung and breast

Figure 3. Regulation of survival and apoptotic signaling proteins by violacein.
(A) Violacein had no effect on pAkt protein levels in solid tumor cell lines
examined, (B) but substantially induced expression of the pro-apoptotic protein cleaved PARP in brain and lung cancer cells. (C) Additionally, violacein
upregulated p44/42 MAPK protein levels in brain tumor cells. Immunoblots
displayed are representative of at least three independent experiments that
showed comparable results.

cancer cells, time course experiments were preformed in the
present study. Examination of U87, A549 and MCF7 cells
treated with 1 µM violacein revealed a reduction in cell
proliferation of all three cell lines over a five-day period,
with a statistically significant difference (P<0.05) in cell
viability observed on day five between vehicle‑treated
control cells and violacein‑treated cells (Fig. 2). Time course
analysis also revealed that U87 and A549 cells were more
sensitive to violacein treatment as compared to MCF7 cells,
which displayed a two-fold increase in cell viability five
days post-violacein treatment as compared to cell viability
on day 0 (Fig. 2). These data were consistent with dose
response experiments that also showed that U87 and A549
cells were more sensitive to violacein exposure than MCF7
cells. The findings of the present study parallel a study by
Menezes et al (34), which showed that crude extracts of
violacein were differentially toxic to several human tumor
cell lines, including the multi‑drug‑resistant ovarian tumor
cell line NCI/ADR-RES.
Violacein promotes PARP and p44/42 mitogen-activated
protein kinase (MAPK) signaling. The mechanistic effects
of violacein on cellular responses have proven to be varied
and tumor type‑specific. Of note, violacein has been shown
to upregulate p53, p27 and p21, which are negative regula-
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Figure 4. Effects of violacein on tumor cell migration. Violacein (A) considerably reduced brain tumor cell migration and (B) had a diminutive effect on lung
cancer cell migration. Shown are boyden chamber assays performed in duplicate that are representative of three independent experiments that exhibited similar
results (magnification, 40x). Aa and Ba, cells treated with vehicle dimethylsulfoxide; Ab and Bb, cells treated with 1 µM violacein. OD, optical density.
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Figure 5. Violacein induces morphological changes that affect tumor cell motility. (A-C) Cells treated with vehicle dimethylsulfoxide. (D) U87 brain tumor
cells displayed a transient round cellular phenotype in response to treatment with 1 µM violacein, that was absent in (E) lung and (F) breast cancer cells.
Micrographs shown are representative of five different experiments that showed similar results (magnification, 100x).

tors of cell cycle progression (24), and to induce reactive
oxygen species‑mediated apoptotic cell death in colon cancer
cells (23). Additionally, Ferreira et al (27) demonstrated that
violacein promoted leukemia cell death via tumor necrosis
factor signaling. To address the mechanisms of the anti‑proliferative response of violacein on solid tumor cells described
above, several intracellular signaling proteins were analyzed
for changes in their expression when exposed to various
concentrations of this agent. The survival and pro-apoptotic
proteins, Akt and PARP, were examined in U87, A549 and
MCF7 cells exposed to violacein. A substantial induction of

cleaved PARP was observed in U87 brain tumor cells treated
with 500 nM violacein, as well as in A549 lung cancer cells
treated with 1 µM violacein (Fig. 3). By contrast, no changes in
the activity of Akt expression were observed in cells exposed
to violacein (Fig. 3). Additional protein expression analysis
revealed that 500 nM violacein upregulated p-44/42 MAPK
in U87 cells. This result was similar to that observed in
leukemia cells, which displayed increased p38 MAPK expression in response to violacein (27). Furthermore, violacein
did not affect the expression levels of pS6 ribosomal protein
(Fig. 3), providing additional evidence along with the lack of

MOLECULAR MEDICINE REPORTS 12: 1443-1448, 2015

expressional changes of pAkt protein described above, that
this secondary metabolite does not mechanistically influence
the translational control signaling network.
Impairment of tumor cell migration in response to violacein.
The effect of violacein on cellular biological processes that
underlie metastatic invasion has not been sufficiently investigated to date, to the best of our knowledge. In the present
study, the ability of violacein to inhibit cellular processes that
contribute to the metastatic invasion of cancers, which leads
to therapeutic resistance and recurrence of this disease, were
therefore evaluated. Boyden chamber assays revealed that
1 µM violacein decreased the migration of U87 cells by 40%
as compared to that of vehicle‑treated control cells, while a
diminutive decrease was observed in A549 violacein‑treated
cells (Fig. 4). The anti‑migratory response, particularly of
U87 cells, may be attributed in part to violacein‑induced
morphological changes (Fig. 5). U87 cells exposed to 500 nM
violacein appeared to detach from the cell substratum and
exhibited a round cellular phenotype three hours post-exposure, which was not observed in A549 and MCF7 cells after
treatment with violacein (Fig. 5). However, cell adhesion assays
performed revealed that violacein did not affect the adhesive
properties of U87 brain tumor cells (data not shown). It should
also be mentioned that U87 cells re‑attached and displayed
normal cell morphology when examined 24 h after violacein
exposure, indicating the violacein‑induced morphological
changes were not a consequence of cells undergoing cell death.
In conclusion, these results suggested that violacein‑induced
morphological changes had an impact on the migratory ability
of U87 brain tumor cells.
Discussion
The efficacy of therapeutic agents used to treat human cancers
is dependent upon their ability to antagonize molecular
signaling events that contribute to the survival of tumor cells
and induce regulatory mechanisms that promote their death.
The present study investigated a novel secondary metabolite,
violacein, produced by a chromobacterium, for its utility as an
agent that can promote tumor cell death in solid tumor‑derived
cell lines. It was shown that violacein considerably reduced
the proliferative capacity of lung and brain cancer cells, and
to a much lesser extent that of breast cancer cells, providing
an indication that cancers are differentially sensitive to this
agent. This difference in sensitivity and responsiveness was
also manifested mechanistically as demonstrated in the
ability of violacein to promote apoptotic cell death by upregulating cleaved PARP, a downstream target of the effector
pro‑apoptotic molecule caspase 3, in brain and lung cancer
cells. Additionally, p44/42, a known apoptosis‑promoting
regulator and caspase 3 activator, was increased in brain
tumor cells treated with violacein. These results established
that violacein‑induced apoptosis observed in the present study
likely occurs via the intrinsic pathway, particularly in brain
tumor cells, which is consistent with studies on leukemia,
fibrosarcoma and colon cancer cells that have demonstrated
the apoptosis‑promoting properties of violacein by intrinsic as
well as extrinsic pathways (23,27,35). It should also be noted
that violacein has been described to elicit other types of cell
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death, as shown in resistant leukemia cells that underwent cell
death as a consequence of endoplasmic reticulum stress and
breakdown of the golgi apparatus, underscoring the tumor cell
killing capacity of violacein via different cell death mechanisms (25).
Although several studies, including the present study, have
provided evidence of violacein's ability to promote tumor
cell death, its role as an agent that can prevent the metastatic invasion of cancer cells has received little attention.
The present study showed that violacein inhibited brain
tumor cell migration, likely as a consequence of disrupting
sub‑cellular domain structures of the actin filamentous
network, including the lamellipodia and filopodia, that led
to a round cellular phenotype that compromised the motility
of these cells. To the best of our knowledge, the present
study was the first to show that violacein inhibits cancer cell
migration, extending the anti‑malignant properties of this
agent. Additionally, the anti‑migratory effects of violacein
on cancer cells demonstrated in the present study are further
supported by a recent study by Platt et al (36), which showed
that violacein inhibited the secretion of the pro-cell migratory inflammatory chemokine CXCL12 in breast cancer cells.
These results suggested that violacein may have therapeutic
applications that prevent brain tumor cells from invading
normal brain tissue, as well as inhibit brain metastases from
breast cancer, the most common source of metastatic brain
tumors in women (30).
In conclusion, violacein has potential as a therapeutic
agent to treat cancer due to its versatility to cause cell death in
several types of cancer and prohibit metastatic invasion. The
potential of violacein to be used as a cancer drug is further
supported by the recent U.S. Federal Drug Administration's
approval of romidepsin, a histone deactylase inhibitor
produced by Chromobacterium violaceum, for the treatment
of T-cell lymphoma (37), as well as a renewed interest in
cancer therapies utilizing bacteria and bacterial products (1-3)
to selectively target cancer cells.
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